Sickle-cell Anemia Therapeutics Market in the US 2015-2019
About Sickle-cell Anemia
Sickle-cell anemia is a disease characterized by the presence of sickle-shaped erythrocytes. While normal erythrocytes have a life span of 120 days, sickle-shaped erythrocytes die within 10 to 20 days. The bone marrow is unable to compensate for the excessive loss of erythrocytes, thereby leading to anemia. It is an inheritable disorder passed on across generations. The prevalence of the sickle-cell gene varies between different ethnic groups and geographical locations.
TechNavio's analysts forecast the Sickle-cell Anemia Therapeutics market in the US to grow at a CAGR of 17.10 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Sickle-cell Anemia Therapeutics market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of the US FDA-approved drugs used for the treatment of sickle-cell anemia.
TechNavio's report, Sickle-cell Anemia Therapeutics Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the Sickle-cell Anemia Therapeutics market landscape in the US and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market..
TechNavio Announces the Publication of its Research Report – Sickle-cell Anemia Therapeutics Market in the US 2015-2019
TechNavio recognizes the following companies as the key players in the Sickle-cell Anemia Therapeutics Market in the US: Bristol-Myers Squibb Co.
Other Prominent Vendors in the market are: Baxter, Bluebird Bio, Daiichi Sankyo, Eli Lilly, Emmaus Medical, GlycoMimetics, HemaQuest Pharmaceuticals, Mast Therapeutics, Merck Sharp & Dohme, Pfizer and Selexys Pharmaceuticals.
Commenting on the report, an analyst from TechNavio’s team said: “Increasing focus on adult patients is one key trend in this market, which is anticipated to provide better healthcare services to adult patients and improve their QoL.”
According to the report, a high degree of unmet medical needs in terms of safe, efficacious, and epilepsy-modifying treatments is one of the major drivers of this market. Any drug that can cater to these demands is expected to drive the market during the forecast period of 2014-2019. .
Further, the report states that the side effects associated with the current therapies are one of the major challenges faced by the market. The more side effects associated with a therapy, the lesser the compliance of patients, which consequently decreases the revenue generation of drugs in the market.Bristol-Myers Squibb, Baxter, Bluebird Bio, Daiichi Sankyo, Eli Lilly, Emmaus Medical, GlycoMimetics , HemaQuest Pharmaceuticals, Mast Therapeutics, Merck Sharp & Dohme, Pfizer, Selexys Pharmaceuticals